Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus palbociclib and letrozole versus placebo plus palbociclib and letrozole in PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer
ISRCTN67316571Phase 3Recruiting
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Experimental Arm: Inavolisib + Letrozole + CDK4/6i with Placebo Comparator Arm: Placebo + Letrozole + CDK4/6i (2 arms). Primary endpoint: Progression-Free Survival. Started Mar 2025; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN67316571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN67316571.